EU to decide on Astrazeneca's $39 bln Alexion deal by July 5

7
2
Favorite

EU to decide on Astrazeneca's $39 bln Alexion deal by July 5

Reuters2021-06-01

BRUSSELS, June 1 (Reuters) - EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.

AstraZeneca sought EU approval on Monday for the deal, its largest ever in a bet on rare-disease immunology and to boost its business, which includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.

The Commission can either clear the deal with or without conditions or it can open a four-month long investigation if it has serious concerns.

The UK Competition Authority and Markets Authority is also reviewing the bid which has already received the green light in the United States, Canada, Brazil and Russia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（2）

March_m
·2021-06-01
AstraZeneca is blooming
Reply
1
Report
CtrlAltDft
·2021-06-01
??
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2140466335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-01 16:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2140466335","market":"uk","top_or_hot":-1,"title":"EU to decide on Astrazeneca's $39 bln Alexion deal by July 5","media":"Reuters","content":"<p>BRUSSELS, June 1 (Reuters) - EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.</p>\n<p>AstraZeneca sought EU approval on Monday for the deal, its largest ever in a bet on rare-disease immunology and to boost its business, which includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.</p>\n<p>The Commission can either clear the deal with or without conditions or it can open a four-month long investigation if it has serious concerns.</p>\n<p>The UK Competition Authority and Markets Authority is also reviewing the bid which has already received the green light in the United States, Canada, Brazil and Russia.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU to decide on Astrazeneca's $39 bln Alexion deal by July 5</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU to decide on Astrazeneca's $39 bln Alexion deal by July 5\n</h2>\n\n<h4 class=\"meta\">\n\n2021-06-01 16:37 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRUSSELS, June 1 (Reuters) - EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALXN","symbol_name":"亚力兄制药","start_time":0,"source_url":null,"article_id":"2140466335","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2140466335","pubTimestamp":1622536621,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"BRUSSELS, June 1 (Reuters) - EU antitrust regulators will decide by July 5 whether to clear Anglo-Sw","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALXN":"亚力兄制药","AZN.UK":"阿斯利康制药","AZN":"阿斯利康"},"translate_title":"欧盟将在7月5日前决定阿斯利康390亿美元的Alexion交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXN":0.9,"AZN":0.9,"AZN.UK":0.9},"content_text":"BRUSSELS, June 1 (Reuters) - EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.\nAstraZeneca sought EU approval on Monday for the deal, its largest ever in a bet on rare-disease immunology and to boost its business, which includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.\nThe Commission can either clear the deal with or without conditions or it can open a four-month long investigation if it has serious concerns.\nThe UK Competition Authority and Markets Authority is also reviewing the bid which has already received the green light in the United States, Canada, Brazil and Russia.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":119609735,"gmtCreate":1622538761627,"gmtModify":1704185885635,"author":{"id":"3580437128970359","authorId":"3580437128970359","authorIdStr":"3580437128970359","name":"March_m","avatar":"https://static.tigerbbs.com/c79c26d5f3dd57115bbcf794ff43dff2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580437128970359"},"htmlText":"AstraZeneca is blooming","listText":"AstraZeneca is blooming","text":"AstraZeneca is blooming","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119609735","repostId":2140466335,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119871653,"gmtCreate":1622538031272,"gmtModify":1704185875200,"author":{"id":"3575179093484917","authorId":"3575179093484917","authorIdStr":"3575179093484917","name":"CtrlAltDft","avatar":"https://static.tigerbbs.com/8018a93a3781a83f157db037ed81237b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575179093484917"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119871653","repostId":2140466335,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":7,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}